alfentanil (alfenta) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Alfentanil is an opioid analgesic with a rapid onset of action. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Alfentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Alfentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Alfentanil, marketed under the trade name Alfenta, Rapifen in Australia is indicated for the management of postoperative pain and the maintenance of general anesthesia.   NCATS

Chemistry

  • SMILES: CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)c3ccccc3)C1=O
  • InChIKey: IDBPHNDTYPBSNI-UHFFFAOYSA-N
  • Mol. Mass: 416.53
  • ALogP: 1.38
  • ChEMBL Molecules:
    alfentanil  
    alfentanil hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0010 - $1.2390
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

afentanyl | alfenta | alfentanil | alfentanil hcl | alfentanil hydrochloride | alfentanilum | alfentanyl | lfentanil hydrochloride | n-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide | r-39209 | rapifen | rapifen conc | rapifen dilute | rapifen intensive care

Organizations (47)

Research & Development (44)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (2)


 

Anesthesia

Pain (approved 1986)

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Acne Vulgaris (Phase 3)

Anesthesia (Phase 4)

Biliary Tract Diseases (Phase 4)

Blood Pressure (Phase 4)

Bronchoscopy (Phase 3)

Confusion (Phase 4)

Conscious Sedation (Phase 4)

Digestive System Diseases (Phase 4)

Electroconvulsive Therapy (Phase 4)

Emergence Delirium (Phase 4)

Esophageal Sphincter, Lower (Phase 4)

Hypoxia (Phase 4)

Intensive Care Units (Phase 3)

Lung Neoplasms (Phase 4)

Morphine (Phase 3)

Neoplasms (Phase 4)

Pain (Phase 4)

Pancreatic Diseases (Phase 4)

Patient Satisfaction (Phase 4)

Pediatrics (Phase 3)

Spinal Stenosis (Phase 2/Phase 3)

Venous Cutdown (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 35
  • # of Trial Organizations: 44

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue